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INTRODUCTION 
Carcinoma cervix is the most common gynaecological malignancy in women. 
Concurrent chemoradiation is the standard of care in locally advanced carcinoma 
cervix. However cytotoxic chemotherapy cannot be safely administered in elderly 
patients and those with pre-existing comorbid medical conditions. Hence pure 
accelerated radiotherapy with intracavitary brachytherapy has been tried in these 
patients. 
AIMS 
1. To assess the immediate locoregional response rates of locally advanced 
carcinomas of cervix treated with pure accelerated EBRT followed by 
intracavitary brachytherapy. 
2. To assess acute toxicities during treatment. 
 
MATERIAL AND METHODS 
This is a single arm prospective study in which 30 patients with squamous cell and 
adenocarcinomas of cervix of stages IIB-IIIB, presenting in Department of 
Radiotherapy, MMC & RGGGH, who were not eligible for chemotherapy due to old 
age, comorbid medical conditions like renal disorders, cardiac diseases etc were 
treated with pure accelerated EBRT- 50 Gy (200 cGy/# in 25#/6 fractions per week) 
followed by intracavitary brachytherapy (7 Gy in 3# in HDR). The response both 
clinical and radiological, was assessed 6 weeks after completion of therapy, using 
RECIST criteria. Toxicity was assessed using RTOG Morbidity scoring. 
RESULTS 
There was complete locoregional response in 23 patients (76.7%), partial response in 
7 patients (23.3%) among whom 4 patients had adenocarcinoma histology. Complete 
response was seen in 85.7% (12/14) and in 62.5% (5/8) of stage IIB and IIIB 
respectively. Acute toxicities were observed but they were manageable. Diarrhoea 
presented as grade 1 in 6 patients (20%) and grade 2 in 3 patients (10%) respectively. 
Grade 1 haematological toxicity was seen in 7 patients (23.3%) during 3rd week of 
radiotherapy and no patients had grade 2 toxicity. Grade 1 and 2 skin reactions were 
seen in 12 patients (40%). The median treatment time for EBRT was 29 days.  
CONCLUSION 
This study shows that pure accelerated EBRT alone followed by brachytherapy is a 
possible alternative in selected patients who are not fit for chemotherapy. The early 
responses are good and acute toxicities are lesser. However, the response of patients 
with adenocarcinoma was poor.  
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